- Report
- February 2025
- 100 Pages
Global
From €5679EUR$5,950USD£4,758GBP
- Report
- May 2024
- 138 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- August 2024
- 170 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- May 2021
- 50 Pages
China
From €2481EUR$2,600USD£2,079GBP
- Report
- November 2023
- 432 Pages
Global
From €9067EUR$9,500USD£7,597GBP
- Report
- January 2024
- 200 Pages
Global
From €3961EUR$4,150USD£3,318GBP
- Report
- August 2019
- 212 Pages
Global
From €14311EUR$14,995USD£11,991GBP
- Report
- January 2024
- 129 Pages
United States
€3627EUR$3,800USD£3,039GBP
- Drug Pipelines
- January 2018
- 13 Pages
Global
From €9544EUR$10,000USD£7,996GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €477EUR$500USD£400GBP
Zytiga is a drug used to treat prostate cancer. It is a type of androgen receptor inhibitor, which works by blocking the action of male hormones that can cause prostate cancer cells to grow. Zytiga is used in combination with prednisone, a steroid, to treat metastatic castration-resistant prostate cancer (mCRPC). It is also used in combination with other drugs to treat non-metastatic castration-resistant prostate cancer (nmCRPC).
Zytiga is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2011. It is now widely used in the treatment of prostate cancer, and is considered to be an important part of the treatment regimen for many patients.
The market for Zytiga is highly competitive, with several companies offering the drug. These include Johnson & Johnson, AbbVie, Astellas Pharma, and Pfizer. Show Less Read more
